To confirm the antitumor effects in vivo, we then performed side-by-side experiments using established CD19 CAR-T cells or control T cells that were intravenously injected into tumor-bearing NOD/Shi-scid IL2rgamma(null) mice on Day 5 of tumor-cell injection. The gene discussed is CD19; the disease is neoplasm.